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Fetal growth restriction (FGR) affects 1200,000 pregnancies in the United States annually and is associated with
increased perinatal mortality and morbidity, as well as poorer long-term health for infants with FGR compared
with infants without FGR. FGR appears to be a complex trait, but the role of genetic factors in the development
of FGR is largely unknown. We conducted a candidate-gene association study of birth weight and FGR in two
independent study samples obtained at the Boston Medical Center. We first investigated the association between
maternal genotypes of 68 single-nucleotide polymorphisms (SNPs) from 41 candidate genes and fetal growth in a
sample of 204 black women selected for a previous study of preeclampsia, 92 of whom had preeclampsia (char-
acterized by high blood pressure and the presence of protein in the urine). We found significant association between
SNP rs2297660 in the LRP8 gene and birth weight. Subsequently, we replicated the association in a larger inde-
pendent sample of 1,094 black women; similar association between LRP8 and FGR was observed in this sample.
The “A” allele at rs2297660 was associated with a higher standardized birth weight and a lower risk of FGR.
Under the additive genetic model, each additional copy of the “A” allele reduced the risk of FGR by 33% (P !
). In conclusion, results from the two independent samples of black women provide consistent evidence that.05
SNP rs2297660 in LRP8 is associated with fetal growth.
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Fetal growth restriction (FGR) essentially describes the
condition of any fetus that does not reach its full growth
potential. In clinical practice, the term is usually reserved
for those infants whose weights are !10th percentile for
the general population at the corresponding gestational
week. FGR is one of the most common fetal abnor-
malities in developed countries1 and affects 1200,000
pregnancies in the United States annually. Perinatal mor-
tality in fetuses with FGR is 5–30 times that in normal
fetuses.2–6 Perinatal asphyxia involving multiple organs
is one of the most significant problems for infants with
FGR. Compared with children without FGR, children
born with FGR demonstrated twice the rate of attention-
deficit/hyperactivity disorder when they were delivered
at full term, and an even higher rate when delivered
preterm.7 Furthermore, there is evidence that individuals
born with FGR are more susceptible to common chronic
adult diseases, such as hypertension, ischemic heart dis-
ease, and diabetes.8–12
Many strategies have evolved to reduce maternal risk
factors associated with FGR, including cessation of
smoking, alcohol use, and drug use; bed rest; nutritional
supplementation; and anticoagulation. At present, there
are no effective treatments for FGR. Antenatal manage-
ment of FGR is largely empirical, aimed primarily at
early identification of at-risk fetuses and selection of the
safest time for delivery. FGR, like other complex dis-
eases, is caused by multiple genetic and environmental
factors and their interactions. The role of genetic factors
in the pathogenesis of FGR remains largely unexplored,
except for some rare cases caused by chromosomal ab-
normalities, single-gene defects, confined placental mo-
saicism, or inherited thrombophilia.13,14 Previous studies
have found that FGR is more common in black women
than in women of other ethnicities.15
Hypertensive disorders, including preeclampsia, eclamp-
sia, and gestational hypertension, significantly increase
the risk of FGR and account for more FGR cases, on a
population basis, than any other medical conditions. Hy-
pertensive disorders of pregnancy affect up to 8% of all
pregnancies and remain the major cause of maternal
and neonatal mortality and morbidity in the United
States and worldwide.16 Chronic hypertension refers to
an elevated blood pressure in the mother that predates
the pregnancy. Women with chronic hypertension enter
pregnancy with a 25%–30% risk of low birth weight
due to a combination of preterm delivery and poor fetal
growth,17,18 and the risk increases with the degree of
hypertension.17,19 When a woman with chronic hyper-
tension develops superimposed preeclampsia, the preg-
nancy is at extremely high risk.17–19
We had previously conducted a candidate-gene study
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of chronic hypertension and preeclampsia in subjects
enrolled at the Boston Medical Center (BMC) (authors’
unpublished data). The purpose of the present study was
to examine in samples from the previous study the as-
sociation between hypertension and/or preeclampsia
candidate genes in mothers and the birth weight of ba-
bies. In addition, we sought to confirm any significant
associations found in the initial analysis by analyz-
ing another independent sample set from the same
population.
Material and Methods
Study Population and Data Collection
This study is part of an ongoing molecular epidemiological
study of preterm birth and low birth weight that has been
conducted at the BMC since 1998. Details on the study site,
the population, and data collection procedures were described
elsewhere.20 Briefly, this is a case-control study in which cases
were defined as either low-birth-weight (!2,500 g) or preterm
(at !37 wk) births. Of the low-birth-weight infants, 38% had
FGR, and 20% had mothers with preeclampsia. Controls were
defined as non–low-birth-weight and non-preterm births. Preg-
nancies resulting in multiple births and newborns with major
birth defects were excluded. The BMC preterm study enrolled
a multiethnic population, of whom 51% were black, 12%
were white, and 26% were Hispanic. Epidemiological and clin-
ical data on each subject, including maternal age, self-reported
ethnicity, parity, prepregnancy height and weight, cigarette
smoking, alcohol drinking, past medical history, and preg-
nancy complications, were collected through a maternal ques-
tionnaire-based interview and a review of medical records.
Maternal venous blood samples were collected postpartum for
nucleic-acid extraction and subsequent laboratory analysis.
The institutional review boards of the BMC, the Massachusetts
Department of Public Health, the Children’s Memorial Hos-
pital in Chicago, and the Harvard School of Public Health
approved the study protocol.
We had previously conducted a candidate-gene study of
preeclampsia in 323 mothers (204 black, 61 Hispanic, and 31
white) enrolled at the BMC (authors’ unpublished data). In
the present study, we first examined the association of the
hypertension and/or preeclampsia candidate genes with FGR
in the sample of 323 women. To minimize population admix-
ture and to ensure adequate sample size, we limited our anal-
ysis to the 204 black women, including 34 cases of FGR. Then,
we sought confirmation of the association in another inde-
pendent sample of black women ( , including 164np 1,094
FGR cases) enrolled at the BMC.
Definition of Fetal Growth Phenotypes
The most commonly used definition of FGR is birth weight
in the lowest 10th percentile of the reference population at the
same gestational week. There are more than a dozen published
birth-weight-for-gestational-age standards, some of which are
widely used in obstetrics, pediatrics, and research.21–23 How-
ever, these published birth-weight cutoff points may differ by
several hundred grams at any gestational age, possibly because
of differences in data sources (hospital- or population-based),
population composition, geographic region, measurement of
gestational age, and exclusion criteria.24,25
Since 1995, the Department of Obstetrics and Gynecology
at the Boston University Medical Center has maintained a com-
puter database of all pregnant women admitted to the BMC
labor and delivery service and the birth outcomes. This da-
tabase now comprises 115,000 deliveries. In this study, we
chose to use this internal population as a reference population,
with exclusion of pregancies with multiple fetuses and new-
borns with major birth defects. We used standardized birth
weight (SBWT) as a continuous measure of fetal growth, where
SBWT is defined as birth weight standardized by the mean and
variance in the stratum of the corresponding ethnic group, sex,
and gestational week in the reference population, as used
widely elsewhere.26–28 We defined FGR as SBWT !10th per-
centile of the SBWT in the reference population.
Candidate-Gene and SNP Selection
In a previous study (authors’ unpublished data), we iden-
tified 129 candidate genes potentially important in preeclamp-
sia and chronic hypertension, the major pathogenic pathways
of FGR, on the basis of biological plausibility and supportive
literature. A total of 576 SNPs in these genes, most of which
are nonsynonymous SNPs, were selected from the public
dbSNP database for verification. Among them, 432 were poly-
morphic in our study population, and 68 were common SNPs
with minor-allele frequency 0.05. To maintain adequate
power, we focused our analysis on the 68 common SNPs,
which spread across 41 genes (table 1).
Extraction of Nucleic Acids and Genotyping
DNA was extracted from samples of venous whole blood
in accordance with standard protocol.29 Verification and initial
genotyping of SNPs were performed by Illumina using the
BeadArray technology. For the confirmatory analysis, SNP
rs2297660 was genotyped using the TaqMan genotyping assay
(Applied Biosystems). PCR was performed in a 5-ml reaction
containing 10 ng of genomic DNA, 1# master mix, 900 nM
of forward and reverse primers, and two 250-nM TaqMan
MGB probes by use of 384-well plates on a PTC-225 Tetrad
Thermal Cycler (MJ Research) under the following conditions:
95C for 10 min and 50 cycles at 92C for 15 s and 60C for
1 min. After PCR, an end-point plate read of the fluorescence
intensity of each well was performed on an ABI Primer 7900
(Applied Biosystems). Genotypes were called automatically us-
ing SDS, version 2.1 (Applied Biosystems), and were inspected
visually on the plot.
All SNPs were in Hardy-Weinberg equilibrium. As a measure
of quality control, we also determined the genotypes at
rs2297660 in 167 subjects obtained from the BeadArray
method in the initial study and found 100% consistency be-
tween the two genotyping methods used in our study.
Statistical Analysis
In both the initial and the confirmatory analyses, we used
a generalized linear model to estimate the effects of genotype
on SBWT and of genotype relative risks on FGR (using the
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Table 1
List of Candidate Genes and SNPs
Biological Pathway
and Gene Symbol Gene Name SNP(s)
Infection/inflammation:
ARTS1 Adipocyte-derived leucine aminopeptidase rs27895, rs26618
ICAM1 Intercellular adhesion molecule 1 rs5491
IL1A Interleukin 1-alpha rs17561
Coagulation:
F5 Coagulation factor V rs6030, rs6019, rs6032
Metabolic:
APOB Apolipoprotein B rs1042031, rs1367117
INSR Insulin receptor rs2963
LRP8 Low-density lipoprotein receptor–related protein 8
(ApoE receptor 2)
rs3737983, rs2297660, rs5174
MTHFR 5,10-Methylenetetrahydrofolate reductase rs1801131
SLC2A2 Solute carrier family 2 rs1800572
Vascular:
ABCC8 ATP-binding cassette, subfamily C, member 8 rs757110
ADRA1A Alpha-1A-adrenergic receptor rs1048101
ADRA1D Alpha-1D-adrenergic receptor rs835879, rs1556832
ADRB2 Beta-2-adrenergic receptor, surface rs1042714
AGTR2 Angiotensin II receptor, type 2 rs5191
APOA4 Apolipoprotein A-IV rs675
ATP1A1 ATPase, Na/K transporting rs1998449
B3GAT1 Beta-1,3-glucuronyltransferase 1 rs1440483, rs1866767
CACNA1C Calcium channel, voltage dependent, L type, alpha-
1C subunit
rs215976
CALCA Calcitonin/calcitonin-related polypeptide, alpha rs5241
CALCRL Calcitonin receptor-like rs696092, rs858745, rs858750, rs3771083,
rs698576, rs698574, rs3771073
DBH Dopamine beta-hydroxylase rs1108580, rs5324, rs4531
EDN1 Endothelin 1 rs2070698, rs5369
EDNRA Endothelin receptor, type A rs702757, rs3942348, rs1517135, rs908581
HCARG Hypertension-related calcium-regulated gene rs1209879
HTR2A 5-hydroxytryptamine (serotonin) receptor 2A rs6314, rs6308, rs6304
KLK1 Kallikrein 1, renal/pancreal/salivary rs3212828
KLKB1 Kallikrein B, plasma (Fletcher factor) 1 rs4253301, rs4253325
KNG Kininogen 1 rs1656922
LPL Lipoprotein lipase rs328
NOS2A Nitric oxide synthase 2A (inducible, hepatocyte) rs2297518, rs3730017
NPPA Natriuretic peptide precursor A rs5063
NPR1 Natriuretic peptide receptor A/guanylate cyclase A rs3891075
NPY2R Neuropeptide Y receptor Y2 rs2880415
NR3C2 Nuclear receptor subfamily 3, group C, member 2 rs5522
PPARGC1 Peroxisome proliferator-activated receptor-gamma,
coactivator 1
rs3736265
PRCP Prolylcarboxypeptidase (angiotensinase C) rs2298668
RENBP Renin-binding protein rs2269371
Other:
GNA11 Guanine nucleotide–binding protein, alpha-11 rs2238625
GNAS GNAS (guanine nucleotide–binding protein, alpha-
stimulating) complex locus
rs7121
PRKCQ Protein kinase C, theta form rs2236379
SLC14A2 Solute carrier family 14, member 2 rs3745009
most frequent homozygote genotype as the reference group),
with adjustment for maternal age, parity, smoking, alcohol
use, and prepregnancy BMI. In addition, we tested for asso-
ciation under additive, dominant, and recessive genetic models.
To test for genotype association with SBWT independent of
preeclampsia, we also performed the regression analyses with
further adjustment for preeclampsia status. To explore possible
genotype interactions with BMI and preeclampsia, we also
estimated the genotype effects on SBWT with stratification on
BMI tertiles and preeclampsia status.
To adjust for multiple tests that we performed in the single-
marker test that included 68 SNPs, each with four models, we
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Table 2
Characteristics of the Black Women Included in the Initial and
Confirmatory Analyses
CHARACTERISTIC
GENETIC ASSOCIATION
ANALYSES
Initial
( )np 204
Confirmatory
( )np 1,094
Age (years) 28.9  7.0 27.9  6.6
Age ! 20 years 26 (12.7) 144 (13.2)
Age 1 35 years 45 (22.1) 179 (16.4)
Heighta (cm) 163.4  6.5 163.9  6.9
Weighta (kg) 71.8  16.5 70.3  17.4
BMIa 26.9  5.9 26.1  6.2
BMIa ! 20 15 (7.4) 133 (12.2)
BMIa 1 30 48 (23.5) 209 (19.1)
Prenatal care during 1st trimester 137 (77) 715 (75.3)
Education (high school or beyond) 138 (68.3) 785 (72.8)
Smoking during pregnancy 27 (13.2) 199 (18.2)
Alcohol use during pregnancy 2 (1) 52 (4.8)b
Drug use during pregnancy 22 (10.8) 129 (11.8)
Married 66 (32.4) 364 (33.3)
C-section delivery 72 (35.3) 325 (30.5)
Parity (1)c 114 (55.9) 684 (62.5)
Diabetes mellitus 4 (2) 16 (1.5)
Gestational diabetes 12 (5.9) 48 (4.4)
Pregnancy-induced hypertensiond 92 (45.1) 46 (4.3)b
Chronic hypertension 48 (23.5) 22 (2.0)b
Gestational age at delivery (wk) 36.7  4.3 38.0  3.4b
Delivery at !37 wk 81 (39.7) 267 (24.4)b
Infant’s birth weight (g) 2,625  957 2,959  775b
Birth weight ! 2,500 g 83 (40.7) 252 (23)b
Birth weight ! 1,500 g 33 (16.2) 57 (5.2)b
SBWT .4  .9 .3  1.0
FGR 34 (16.9) 164 (15.1)
NOTE.—Data for quantitative variables are given as mean  SD.
All other data are no. (%) of subjects.
a Before pregnancy.
b , obtained by two-tailed t test or x2 test.P ! .05
c “1” means at least one previous birth.
d Also includes preeclampsia, eclampsia, and HELLP syndrome (a
syndrome characterized by hemolysis, elevated liver enzyme levels, and
low platelet count).
performed a permutation procedure to obtain empirical P val-
ues for assessment of global significance. In the permutation
procedure, we first established an SBWT predictive model in
our study sample, using maternal age, parity, smoking, alcohol
use, and BMI as covariates, and we calculated the SBWT res-
idue from the predictive model in each subject. In each cycle
of permutation, we randomly assigned study subjects to one
of the calculated SBWT residues and performed regression
analysis on all the genetic models for each SNP, with SBWT
residue as the dependent variable. We recorded the minimal P
value (Ppermute) among the analyses for all possible combinations
of SNPs and genetic models in the cycle. We performed a total
of 1,000 permutation cycles and correspondingly obtained
1,000 minimal P values. The global P values of our tests were
determined empirically as . AllP p P(P  P )global observed permute
analyses were performed using the R statistical package (The
R Project for Statistical Computing).
We also performed haplotype association analysis on the
three SNPs (rs5174, rs3737983, and rs2297660) in the LRP8
gene (MIM 602600). We first checked the haplotype structure
of LRP8 in the Africa American population derived from the
International HapMap Project,30 using HaploView,31 and we
found that the three SNPs were in a single block. Then, we
performed haplotype association analysis on SBWT, using the
Haplo.Stat package32 and adjusting for all covariates, as in the
single-marker tests.
Results
Phenotypic Characteristics
Our initial and confirmatory analyses consisted of 204
and 1,094 black women selected from the BMC preterm
cohort, respectively. The initial-analysis samples were
originally selected for a case-control study on preeclamp-
sia, whereas the confirmatory-analysis samples were se-
lected from all available subjects in the BMC cohort at
the time of the study who were not in the initial analysis.
The phenotypic characteristics of the two analysis sam-
ples are summarized in table 2. The distributions of age,
prepregnancy height, weight, prenatal care during 1st
trimester, education level, marital status, and parity were
similar in both study samples. Compared with women
in the initial sample, women in the confirmatory sam-
ple were more likely to drink alcohol during pregnancy;
had much lower prevalences of preeclampsia (4.3% vs.
45.1%), preterm deliveries (24.4% vs. 39.7%), and
chronic hypertension (2.0% vs. 23.5%); had a longer
mean gestation (38.0 wk vs. 36.7 wk); and had babies
with a higher mean birth weight (2,959 g vs. 2,625 g).
In addition, subjects in the confirmatory sample tended
to have a slightly lower BMI and a higher percentage of
cigarette smoking, although the differences were not sta-
tistically significant. The distribution of SBWT in both
study samples was approximately normal, with a slight
shift of the mean to the left in the initial sample (fig. 1).
The prevalence of FGR in both study samples was also
quite similar and was significantly higher than that in
the general population.
The Initial Association Analysis
In the screening analysis, we tested 68 SNPs from 41
candidate genes for association with fetal growth in 204
black women. We found suggestive evidence of associ-
ation with SBWT for six SNPs in five genes, with an
unadjusted P value !.01 in at least one of the tests (table
3). It is noteworthy that all three SNPs in LRP8 were
associated with SBWT. In particular, the association be-
tween rs2297660 and SBWT (unadjusted ; ad-P ! .0001
justed global ) was statistically significant evenP ! .01
after adjustment for multiple tests. The birth weights for
maternal rs2297660 genotypes AC and AA were 0.48
SD and 0.67 SD higher, respectively, than that for ma-
ternal genotype CC. The three LRP8 SNPs were in high
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Table 3
Selected Results from the Initial Association Analysis of SBWT
Gene, SNP,
and Genotype
No. of
Women b Praw Pglobal
Genetic
Model
LRP8:
rs2297660: .44 .00004 .004 Additive
CC 130
CA 63
AA 11
rs3737983: .36 .0005 .04 Additive
CC 114
CT 76
TT 14
KLK1:
rs3212828: .36 .004 .30 Additive
GG 146
GA 54
AA 4
CALCRL:
rs698576: .40 .007 .46 Additive
GG 162
GA 41
AA 1
KNG:
rs1656922: .44 .007 .46 Recessive
TT 80
TC 86
CC 38
F5:
rs6019: .40 .013 .70 Recessive
GG 66
GC 99
CC 39
NOTE.—Results were computed using a generalized linear model,
and only those with are listed.P ! .01
Figure 1 A, Distribution of SBWT for the subjects included in the screening study ( ). B, Distribution of SBWT for the subjectsnp 204
included in the validation study ( ).np 1,094
linkage disequilibrium in our samples and were found
to be in a single haplotype block in both samples (data
not shown). Haplotype analysis with the three SNPs pro-
duced a blockwide P value of .0004 (table 4). Among
all single-marker and haplotype tests on the three SNPs
under different genetic models, the strongest association
observed was between rs2297660 and SBWT under an
additive genetic model. As a result, we sought confir-
mation of the association between rs2297660 and SBWT
in another independent sample.
The Confirmatory and Pooled Analyses
The association between rs2297660 and SBWT was
successfully replicated in 1,094 black women selected
from the same BMC preterm cohort who were indepen-
dent from the initial study sample ( ) (table 5).P ! .05
However, the differences in the magnitude of the esti-
mated effects of different genotypes on SBWT were
smaller in the confirmatory analysis than in the ini-
tial analysis. In addition, we estimated the effects of
rs2297660 genotype and other covariates on FGR in the
pooled sample (table 6). The “A” allele at rs2297660
was associated with a higher SBWT and a lower risk of
FGR. Under the additive genetic model, each additional
copy of the “A” allele reduced the risk of FGR by 33%
( ).P ! .05
Discussion
Preeclampsia is one of the most important risk factors
for FGR. In this study, we examined 68 common SNPs
in the candidate genes identified on the basis of the major
pathogenic pathways from preeclampsia or chronic hy-
pertension to birth weight. We demonstrated a signifi-
cant association between SNP genotypes in the maternal
LRP8 gene and birth weight in two independent samples
of black women selected from the BMC preterm cohort.
The observed association was independent of preeclamp-
sia status, because there were few changes in estimated
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Table 4
Result of Haplotype Analysis of Association
between LRP8 and SBWT
HAPLOTYPE
HAPLOTYPE
FREQUENCY Pars5174 rs3737983 rs2297660
G C C .74 .003
G T C .05 .36
G T A .14 .018
A T A .07 .009
a P values were obtained using the haplotype test imple-
mented in Haplo.Stat. The global haplotype .Pp 0
Table 5
Results of Analyses of Association between rs2297660 and SBWT
GROUP AND
rs2297660
GENOTYPE
NO. OF
WOMEN
MEAN (SD)
SBWT
CRUDE
ANALYSIS
ADJUSTED
ANALYSISa
b SE P b SE P
Screening study:
CC 130 .58  .88 Ref … … Ref … …
AC 63 .08  .80 .50 .13 .0002 .48 .13 .0004
AA 11 .16  1.11 .74 .29 .01 .67 .29 .02
Additiveb … .05  .85 .44 .11 .00004 .41 .11 .0001
Validation study:
CC 541 .26  .98 Ref … … Ref … …
AC 245 .14  1.02 .12 .08 .12 .11 .08 .14
AA 46 .03  .99 .29 .15 .06 .26 .15 .08
Additiveb … .11  1.02 .13 .06 .025 .12 .06 .035
Pooled analysis:
CC 671 .32  .97 Ref … … Ref … …
AC 308 .13  .98 .19 .07 .004 .19 .07 .005
AA 57 .05  1.00 .37 .14 .006 .35 .13 .01
Additiveb … .10  .99 .19 .05 .0002 .18 .05 .0004
NOTE.—Ref p reference.
a Controlled for age, parity, smoking, and BMI.
b In additive model, CC p 0, AC p 1, and AA p 2.
genotype effects on SBWT and in levels of significance
in the regression analyses with and without adjustment
for preeclampsia status. To our knowledge, this is the
largest genetic association study of birth weight and FGR
in the United States and is the first to implicate maternal
LRP8 polymorphisms in the regulation of birth weight
among infants of black mothers.
The LRP8 gene, located on chromosome 1p34, con-
sists of 19 exons spanning ∼60 kb and encodes apoli-
poprotein E (ApoE) receptor 2, which mediates the cel-
lular recognition and internalization of ApoE-containing
lipoproteins.33 ApoE is one of the most important reg-
ulators of plasma lipids and affects hepatic binding, up-
take, and catabolism of several classes of lipoproteins.34
The predicted structure of ApoE receptor 2 contains 963
aa, including a putative 41-aa signal sequence and five
functional domains that resemble those of the low-den-
sity lipoprotein receptor and the very-low-density lipo-
protein receptor. LRP8 is highly expressed in human
brain and placenta,35 and its expression is essential for
neural development in mice.36 The molecular mecha-
nisms underlying the association between LRP8 and
birth weight is unknown, although the gene’s high ex-
pression level in placenta hints at a possible role in the
regulation of the microenvironment of fetal growth.
Of the three LRP8 SNPs that were associated with
birth weight, rs2297660 produced the strongest asso-
ciation. The rs2297660 polymorphism elicits a silent nu-
cleotide CrA substitution in the 3rd nucleotide of the
419th codon of LRP8 and does not cause any changes
in the structure of the product. We can speculate three
mutually exclusive scenarios that might explain the ob-
served association. First, the nucleotide substitution at
rs2297660 might affect the stability or translation effi-
ciency of the transcript. Second, the SNP could be in
linkage disequilibrium with a true causal variant in close
proximity. Third, the association could be spurious. The
fact that the same association was replicated in an in-
dependent sample in our study suggests that the third
scenario is unlikely.
Although we observed a significant association be-
tween rs2297660 and SBWT in both study samples, the
estimate of the genotype effects from the initial analysis
was ∼3 times larger than that from the confirmatory
analysis. The major difference between these two study
samples is the 10-fold higher percentage of preeclamptic
subjects in the initial sample than in the confirmatory
one (45.1% vs. 4.3%). In our stratified analysis, the
estimated genotype effect was slightly larger in pre-
eclamptic subjects than in non-preeclamptic subjects, al-
though this difference was not statistically significant
( ) (table 7). The effects of rs2297660 genotypePp .48
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Table 6
Odds Ratios of FGR for rs2297660 Genotype
and Other Covariates in the Pooled Sample
Covariate OR (95% CI) P
rs2297660a .67 (.48–.94) .02
Age .97 (.94–1.00) .03
Parity 1.01 (.87–1.18) .8
Smoking 1.87 (1.18–2.98) .008
BMI .99 (.96–1.02) .6
PIHb 3.16 (1.96–5.09) .000002
NOTE.—FGR was defined as SBWT !10th
percentile of the SBWT in the reference
population.
a For rs2297660 genotype, an additive model
was used.
b PIH p pregnancy-induced hypertension.
Table 7
Association of LRP8 rs2297660 Genotype and SBWT, Stratified
by Pregnancy-Induced Hypertension (PIH) Status
GROUP AND
rs2297660
GENOTYPE
NO. OF
WOMEN
CRUDE
ANALYSIS
ADJUSTED
ANALYSISa
b SE P b SE P
PIH group: .30 .17 .08 .23 .18 .19
CC 73
AC 32
AA 7
Non-PIH group: .18 .05 .0008 .17 .05 .001
CC 581
AC 264
AA 49
NOTE.—An additive inheritance model was used.
a Controlled for age, parity, smoking, and BMI.
were 1.35 times larger in preecalmptic subjects than in
non-preeclamptic subjects.
This study focuses on black women enrolled in the
BMC preterm study. The assignment of ethnicity was
based on self-reported ethnicity on the questionnaire.
The information available does not allow us to further
categorize subjects into subpopulations. In the present
study, as in most other population-based association
studies, population admixture could be an issue that
could cause spurious association results.37 In a previous
study, we applied a clustering method based on a Bayes-
ian model, to divide subjects enrolled in the BMC pre-
term study into groups of blacks, Hispanics, and whites
on the basis of the genotypes of 31 markers. We found
that the self-reported ethnicity groups accounted for, on
average, 95% of the underlying admixture.38 It has been
suggested that the effects of such admixture can be
detected and adjusted for by using a large number of
random markers (genomic controls).39 Although this
strategy works well in case-control designs, it is not
straightforwardly applicable to association tests of quan-
titative traits like those used in this study.
The frequency of the “A” allele (the protective allele)
of rs2297660 was 0.20 in the black sample in our study.
In samples of a limited number of white subjects (np
; 0 cases of FGR) and Hispanic subjects ( ; 1131 np 61
cases of FGR) who we genotyped, the frequency of the
“A” allele was 0.31 and 0.37, respectively. The low fre-
quency of the protective allele in blacks is consistent with
the high prevalence of FGR among blacks. However, the
question of whether LRP8 explains racial disparity of
FGR requires further data and analyses.
In summary, we have, for the first time, demonstrated
a replicable association between maternal genotype of
the LRP8 gene and birth weight in black women enrolled
at BMC. It will be important to replicate this finding
in other study populations and ethnic groups, as well as
to examine the effects of LRP8 genotypes in infants
and the possible interactions between maternal and in-
fant genotypes. If our findings are confirmed, further
study will be warranted to identify functional variants
in this gene and to elucidate the underlying biological
mechanisms.
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